These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23893876)

  • 1. Multiplicity: discussion points from the Statisticians in the Pharmaceutical Industry multiplicity expert group.
    Phillips A; Fletcher C; Atkinson G; Channon E; Douiri A; Jaki T; Maca J; Morgan D; Roger JH; Terrill P
    Pharm Stat; 2013; 12(5):255-9. PubMed ID: 23893876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Missing data: discussion points from the PSI missing data expert group.
    Burzykowski T; Carpenter J; Coens C; Evans D; France L; Kenward M; Lane P; Matcham J; Morgan D; Phillips A; Roger J; Sullivan B; White I; Yu LM;
    Pharm Stat; 2010; 9(4):288-97. PubMed ID: 19844946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to multiplicity in publicly funded pragmatic randomised controlled trials: a survey of clinical trials units and a rapid review of published trials.
    Pike K; Reeves BC; Rogers CA
    BMC Med Res Methodol; 2022 Feb; 22(1):39. PubMed ID: 35125091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan.
    Sakamaki K; Morita Y; Iba K; Kamiura T; Yoshida S; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1097-1105. PubMed ID: 32030692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimands: discussion points from the PSI estimands and sensitivity expert group.
    Phillips A; Abellan-Andres J; Soren A; Bretz F; Fletcher C; France L; Garrett A; Harris R; Kjaer M; Keene O; Morgan D; O'Kelly M; Roger J
    Pharm Stat; 2017 Jan; 16(1):6-11. PubMed ID: 26997517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidelines for multiplicity adjustment in clinical trials.
    Proschan MA; Waclawiw MA
    Control Clin Trials; 2000 Dec; 21(6):527-39. PubMed ID: 11146147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An introduction to multiplicity issues in clinical trials: the what, why, when and how.
    Li G; Taljaard M; Van den Heuvel ER; Levine MA; Cook DJ; Wells GA; Devereaux PJ; Thabane L
    Int J Epidemiol; 2017 Apr; 46(2):746-755. PubMed ID: 28025257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):169-188. PubMed ID: 29125802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traditional multiplicity adjustment methods in clinical trials.
    Dmitrienko A; D'Agostino R
    Stat Med; 2013 Dec; 32(29):5172-218. PubMed ID: 24114861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues of simultaneous tests for noninferiority and superiority.
    Ng TH
    J Biopharm Stat; 2003 Nov; 13(4):629-39; discussion 641-62. PubMed ID: 14584713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians.
    Huitfeldt B; Hummel J;
    Pharm Stat; 2011; 10(5):414-9. PubMed ID: 21932294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous testing of noninferiority and superiority increases the false discovery rate.
    Ng TH
    J Biopharm Stat; 2007; 17(2):259-64. PubMed ID: 17365222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Traditional multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):146-168. PubMed ID: 29172961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group.
    Phillips AJ; Keene ON;
    Pharm Stat; 2006; 5(1):61-6. PubMed ID: 17080929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the role and function of trial steering committees: results of an expert panel meeting.
    Harman NL; Conroy EJ; Lewis SC; Murray G; Norrie J; Sydes MR; Lane JA; Altman DG; Baigent C; Bliss JM; Campbell MK; Elbourne D; Evans S; Sandercock P; Gamble C
    Trials; 2015 Dec; 16():597. PubMed ID: 26715378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical Interactions in a Clinical Trial.
    Ting N
    Ther Innov Regul Sci; 2018 Jan; 52(1):14-21. PubMed ID: 29714613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints.
    Sun H; Snyder E; Koch GG
    J Biopharm Stat; 2018; 28(1):189-211. PubMed ID: 28992425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to deal with multiple treatment or dose groups in randomized clinical trials?
    Hothorn LA
    Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.